Actin bundling protein fascin expression in ovarian neoplasms: comparison of histopathologic features of tumors obtained by the first and secondary cytoreduction surgeries.
OBJECTIVE
The aim of the study was to compare the fascin expression pattern and histopathologic features of malign epithelial ovarian tumors obtained by the primary and secondary surgeries.


METHODS
The samples of 94 epithelial ovarian carcinomas, 35 secondary surgeries for ovarian carcinomas, 13 borderline epithelial ovarian tumors, 25 cystadenomas and four normal ovarian tissues were stained by means of fascin immunohistochemistry. Secondary surgeries included in the study were secondary cytoreduction at the time of second-look laparotomy (SLL), interval debulking surgery after neoadjuvant chemotherapy or secondary cytoreductive surgery in patients with recurrent epithelial ovarian carcinoma.


RESULTS
Mean rank value of the stromal fascin score was higher in 94 cases of malign epithelial ovarian carcinomas than borderline epithelial tumors, cystadenomas and normal ovaries (.000, p < 0.001). There was no significant difference in terms of total epithelial fascin score (.685, p > 0.05) and total stromal fascin score (.572, p > 0.05) between the primary and the secondary surgeries of epithelial ovarian carcinomas.


CONCLUSIONS
Regarding the results of stromal fascin expression in 94 epithelial ovarian carcinomas, we hypothesized that cell-matrix interaction was an important step in the progression of malign epithelial ovarian neoplasms. Our study showed that the initial tumorigenic phenotype did not change with time and use of cisplatinum-based combination chemotherapy. Further studies with close follow-up of patients are necessary to reveal the role of fascin on matrix degradation mechanisms which might be the cause of the recurrences in ovarian neoplasms.
Kabukcuoglu
S
S
Department of Pathology, University of Eskisehir Osmangazi School of Medicine, Eskisehir, Turkey.
Ozalp
S S
SS
Oner
U
U
Bildirici
K
K
Yalcin
O T
OT
Oge
T
T
Colak
E
E
D000199:Actins / Q000378:metabolism*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002352:Carrier Proteins / Q000378:metabolism*; D002945:Cisplatin / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007813:Laparotomy; D008840:Microfilament Proteins / Q000378:metabolism*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000601:surgery*; D009375:Neoplasms, Glandular and Epithelial; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery*; D011183:Postoperative Complications / Q000453:epidemiology; D012086:Reoperation; D024162:Second-Look Surgery
D000199:Actins; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D004338:Drug Combinations; D008840:Microfilament Proteins; C020324:fascin; D002945:Cisplatin